Cannabis Use Was Linked to One Sleep Complaint but Not Others in Older Pain Patients

Sleep is not one interchangeable outcome. A cross-sectional study in older adults with chronic pain linked medical cannabis use to fewer nighttime-waking problems, while other sleep complaints did not differ between users and non-users.

A comparison of existing users and non-users

The study recruited 128 patients over fifty years old, including sixty-six medical cannabis users and sixty-two non-users. Regression analyses accounted for several measured characteristics, including pain and medication use. Participants were not randomized to begin cannabis treatment.

Results differed by the sleep question

After adjustment, cannabis use was associated with fewer problems waking during the night. The abstract reports no group difference in difficulty falling asleep or waking early without returning to sleep. Among cannabis users, more frequent use was associated with greater problems on some sleep measures.

Frequency does not establish the direction of cause

Frequent use might contribute to adaptation, but people with worse symptoms might also use more often. A single cross-sectional assessment cannot establish which came first. Statistical adjustment for measured variables does not remove every difference between people who choose cannabis and those who do not.

The study supports separating sleep onset, nighttime maintenance and early waking rather than declaring that cannabis uniformly improves sleep. It also does not establish a personal dosing schedule, a driving-clearance interval or a causal tolerance mechanism. Clinical and forensic accounts should identify the specific complaint, the treatment history and whether the evidence measures an association or a change caused by treatment.

Related: interpreting cannabis tolerance claims.

Research cited

Sznitman SR; Vulfsons S; Meiri D; Weinstein G. Medical cannabis and insomnia in older adults with chronic pain: a cross-sectional study. BMJ supportive & palliative care (2020). doi:10.1136/bmjspcare-2019-001938. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us